Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TAG vaccine (Sarah Cannon Research Institute)
- Development stage
- Unknown
- Lead developer
- Sarah Cannon Research Institute
- Modality
- Vaccines & Immunotherapeutics, Cell Therapies, Gene Therapies
- Administration
- Intradermal
01
Overview
The TAG vaccine is an autologous, whole-tumor cell vaccine developed by the Mary Crowley Medical Research Center in collaboration with Gradalis. It consists of a patient's own tumor cells that have been genetically modified via electroporation with a dual-expression plasmid. This plasmid contains two functional components: a gene encoding human granulocyte-macrophage colony-stimulating factor (GM-CSF) and a TGFβ2 antisense nucleotide sequence. The GM-CSF component serves to recruit and activate dendritic cells and other antigen-presenting cells to the vaccination site, while the TGFβ2 antisense component inhibits the production of the immunosuppressive cytokine TGFβ2 by the tumor cells. By simultaneously enhancing immune stimulation and reducing tumor-mediated immune evasion, the vaccine aims to induce a systemic anti-tumor immune response against the full array of the patient's specific tumor antigens. It has been investigated in Phase I trials for advanced metastatic solid tumors.
- Other names
- TGFβ2 Antisense-GMCSF Gene Modified Autologous Tumor Cell VaccineAuto TAG vaccine
02
Targets
GM-CSF (Granulocyte-macrophage colony-stimulating factor)CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)TGFB2 (Transforming growth factor beta 2)
Beyond the preview
Go deeper on TAG vaccine (Sarah Cannon Research Institute).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TAG vaccine (Sarah Cannon Research Institute).